Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine
Baxiva, an ETH Zurich spin-off, received CHF 150,000 from Venture Kick to advance a first-in-class Escherichia coli glycoconjugate vaccine. The company aims to reduce urinary tract infections and antibiotic use by progressing its lead program to partner-ready status and engaging global vaccine manufacturers.
Why it mattersVenture Kick's CHF 150,000 award enables Baxiva to make its E.